Aarkstore - Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014 - PowerPoint PPT Presentation

About This Presentation
Title:

Aarkstore - Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014

Description:

This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Browse full report @ – PowerPoint PPT presentation

Number of Views:93

less

Transcript and Presenter's Notes

Title: Aarkstore - Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2014


1
Type 1 Diabetes (Juvenile Diabetes) - Pipeline
Review, H2 2014
Pharmaceuticals Healthcare Market Research
Reports
2
Summary
  • Type 1 Diabetes (Juvenile Diabetes) - Pipeline
    Review, H2 2014, provides an overview of the Type
    1 Diabetes (Juvenile Diabetes)s therapeutic
    pipeline.This report provides comprehensive
    information on the therapeutic development for
    Type 1 Diabetes (Juvenile Diabetes), complete
    with comparative analysis at various stages,
    therapeutics assessment by drug target, mechanism
    of action (MoA), route of administration (RoA)
    and molecule type, along with latest updates, and
    featured news and press releases. It also reviews
    key players involved in the therapeutic
    development for Type 1 Diabetes (Juvenile
    Diabetes) and special features on late-stage and
    discontinued projects.
  • Global Markets Directs report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team.

3
Scope
  • - The report provides a snapshot of the global
    therapeutic landscape of Type 1 Diabetes
    (Juvenile Diabetes)- The report reviews key
    pipeline products under drug profile section
    which includes, product description, MoA and RD
    brief, licensing and collaboration details
    other developmental activities - The report
    reviews key players involved in the therapeutics
    development for Type 1 Diabetes (Juvenile
    Diabetes) and enlists all their major and minor
    projects- The report summarizes all the dormant
    and discontinued pipeline projects - A review of
    the Type 1 Diabetes (Juvenile Diabetes) products
    under development by companies and
    universities/research institutes based on
    information derived from company and
    industry-specific sources- Pipeline products
    coverage based on various stages of development
    ranging from pre-registration till discovery and
    undisclosed stages- A detailed assessment of
    monotherapy and combination therapy pipeline
    projects- Coverage of the Type 1 Diabetes
    (Juvenile Diabetes) pipeline on the basis of
    target, MoA, route of administration and molecule
    type- Latest news and deals relating related to
    pipeline products

4
Reasons to buy
  • - Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies- Identify
    emerging players with potentially strong product
    portfolio and create effective counter-strategies
    to gain competitive advantage- Develop strategic
    initiatives by understanding the focus areas of
    leading companies- Identify and understand
    important and diverse types of therapeutics under
    development for Type 1 Diabetes (Juvenile
    Diabetes)- Plan mergers and acquisitions
    effectively by identifying key players of the
    most promising pipeline- Devise corrective
    measures for pipeline projects by understanding
    Type 1 Diabetes (Juvenile Diabetes) pipeline
    depth and focus of Indication therapeutics-
    Develop and design in-licensing and out-licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope- Modify the
    therapeutic portfolio by identifying discontinued
    projects and understanding the factors that drove
    them from pipeline

5
Table of Content
  • Introduction 7Type 1 Diabetes (Juvenile
    Diabetes) Overview 8Therapeutics Development
    9Type 1 Diabetes (Juvenile Diabetes) -
    Therapeutics under Development by Companies
    11Type 1 Diabetes (Juvenile Diabetes) -
    Therapeutics under Investigation by
    Universities/Institutes 20Type 1 Diabetes
    (Juvenile Diabetes) - Pipeline Products Glance
    22Type 1 Diabetes (Juvenile Diabetes) - Products
    under Development by Companies 26Type 1 Diabetes
    (Juvenile Diabetes) - Products under
    Investigation by Universities/Institutes 38Type
    1 Diabetes (Juvenile Diabetes) - Companies
    Involved in Therapeutics Development 40Type 1
    Diabetes (Juvenile Diabetes) - Therapeutics
    Assessment 135Drug Profiles 147Type 1 Diabetes
    (Juvenile Diabetes) - Recent Pipeline Updates
    400Type 1 Diabetes (Juvenile Diabetes) - Dormant
    Projects 476Type 1 Diabetes (Juvenile Diabetes)
    - Discontinued Products 479Type 1 Diabetes
    (Juvenile Diabetes) - Product Development
    Milestones 480Appendix 489

6
List of Tables
  • Number of Products under Development for Type 1
    Diabetes (Juvenile Diabetes), H2 2014 30Number
    of Products under Development for Type 1 Diabetes
    (Juvenile Diabetes) - Comparative Analysis, H2
    2014 31Number of Products under Development by
    Companies, H2 2014 33Number of Products under
    Development by Companies, H2 2014 (Contd..1)
    34Number of Products under Development by
    Companies, H2 2014 (Contd..2) 35Number of
    Products under Development by Companies, H2 2014
    (Contd..3) 36Number of Products under
    Development by Companies, H2 2014 (Contd..4)
    37Number of Products under Development by
    Companies, H2 2014 (Contd..5) 38Number of
    Products under Development by Companies, H2 2014
    (Contd..6) 39Number of Products under
    Development by Companies, H2 2014 (Contd..7)
    40Number of Products under Investigation by
    Universities/Institutes, H2 2014 42Comparative
    Analysis by Late Stage Development, H2 2014
    43Comparative Analysis by Clinical Stage
    Development, H2 2014 44Comparative Analysis by
    Early Stage Development, H2 2014 45

7
List of Figures
  • Number of Products under Development for Type 1
    Diabetes (Juvenile Diabetes), H2 2014 30Number
    of Products under Development for Type 1 Diabetes
    (Juvenile Diabetes) - Comparative Analysis, H2
    2014 31Number of Products under Development by
    Companies, H2 2014 32Number of Products under
    Investigation by Universities/Institutes, H2 2014
    41Comparative Analysis by Late Stage
    Development, H2 2014 43Comparative Analysis by
    Clinical Stage Development, H2 2014
    44Comparative Analysis by Early Stage Products,
    H2 2014 45Assessment by Monotherapy Products, H2
    2014 156Assessment by Combination Products, H2
    2014 157Number of Products by Top 10 Targets, H2
    2014 158Number of Products by Stage and Top 10
    Targets, H2 2014 158Number of Products by Top 10
    Mechanism of Actions, H2 2014 161Number of
    Products by Stage and Top 10 Mechanism of
    Actions, H2 2014 161Number of Products by Top 10
    Routes of Administration, H2 2014 164Number of
    Products by Stage and Top 10 Routes of
    Administration, H2 2014 164

8
Browse Full Report
  • Or Sample Request _at_
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/60608/type-1-diabetes-juvenile-diabetes-pipeline
    -review-h2-2014

9
Related Reports
  • Fabry Disease-Pipeline Insights, 2015
  • Ocular Hypertension-Pipeline Insights, 2015
  • Fallopian Tube Cancer-Pipeline Insights, 2015
  • Ocular Inflammation-Pipeline Insights, 2015
  • Familial Adenomatous Polyposis Coli-Pipeline
    Insights, 2015
  • Ocular Pain-Pipeline Insights, 2015
  • Familial Amyloid Polyneuropathy (Transthyretin
    Amyloidosis, Corino de Andrades Disease)-Pipeline
    Insights, 2015
  • Oligodendroglioma-Pipeline Insights, 2015

10
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
11
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
Write a Comment
User Comments (0)
About PowerShow.com